Be Part of the Future: AiBtl BioPharma’s Upcoming IPO
AiBtl BioPharma is on the path to becoming a publicly traded company. We have officially filed our S-1 and are preparing for our IPO in Summer 2025. This marks a pivotal moment in our journey as we bring cutting-edge biotech innovations to the global market.
With AI-driven digital health solutions, global research partnerships, and a rapidly growing pipeline, AiBtl BioPharma is positioned for long-term growth and value creation. Now is the time to invest in the next generation of biotech.
Why Invest in AiBtl BioPharma?
- ✔ Upcoming IPO – Get in early as we transition into a publicly traded company.
- ✔ Strategic Global Partnerships – Leverage our strong relationships with premier medical research institutions, providing access to world-class innovation.
- ✔ High-Growth Market – Attention Deficit Hyperactivity Disorder is one of the most common neurodevelopmental disorders, affecting both children and adults worldwide. The global ADHD market was valued at USD 16.2 billion in 2023 and is projected to grow to USD 30.6 billion by 2032, at a compound annual growth rate (“CAGR”) of 7.3%. The Antidepressants Market Size was valued at USD 19.92 Billion in 2023 and is projected to reach USD 37.44 Billion by 2032 and grow at a CAGR of 7.66%.
IPO Timeline & Next Steps
- 🔹 S-1 Filing Completed – Regulatory filing submitted and under review.
- 🔹 Roadshow Begins – Engage with our leadership team and learn about our vision.
- 🔹 IPO Launch – Summer 2025 – Secure your opportunity before we go public.
Secure Your Position Today
AiBtl BioPharma’s IPO presents an exclusive opportunity for investors looking to capitalize on the future of biotech innovation. Fill Out the Form Below to connect with our Investor Relations team.
- 🔹 Request Our Investor Deck
- 🔹 Schedule a Meeting with Our IPO Team
- 🔹 Sign Up for Investor Alerts